信诺(CI)最主要的收入来源是什么？

通过最新财报数据拆解，该公司的收入主要由其核心业务板块与相关服务支持构成。您可以通过页面上的交互式图表直观查看各业务线对总营收的具体贡献比例。

如何直观分析 CI 的财务状况与盈利模式？

瓜壳日历通过交互式桑基图(Sankey Diagram)和瀑布图(Waterfall Chart)，将该公司的总营收、销售成本、运营费用以及最终的净利润流程进行了全景可视化，方便投资者一分钟看懂其经营效率与现金流走向。

Income Statement Q1 2026
Item	Category	Value	YoY
Total revenues	revenue	68.49B	4.57%
Net investment gains (losses)	revenue	258.00M	12800.00%
Gain on sale of businesses	revenue	11.00M	-73.17%
Income from operations	profit	2.36B	19.63%
Total benefits and expenses	cost	66.14B	4.10%
Aggregate	revenue	2.63B	30.57%
Pharmacy and other service costs	cost	54.10B	11.78%
Medical costs and other benefit expenses	cost	7.92B	-24.52%
Selling, general and administrative expenses	cost	3.72B	-11.65%
Amortization of acquired intangible assets	cost	390.00M	-7.58%
Income before income taxes	profit	2.27B	37.74%
Interest expense and other	revenue	357.00M	-1.38%
Net income	profit	1.86B	32.08%
Income tax expense (benefit)	cost	409.00M	71.13%
Shareholders' net income	profit	1.65B	25.02%
Less: net income attributable to noncontrolling interests	cost	207.00M	140.70%

Balance Sheet Q1 2026
Item	Category	Value
Accounts receivable, net	assets	26.61B
Cash and cash equivalents	assets	7.04B
Inventories	assets	5.83B
Other current assets	assets	2.74B
Current investments	assets	812.00M
Total current assets	assets	43.03B
Goodwill	assets	45.53B
Other intangible assets	assets	27.32B
Investments per consolidated balance sheets	assets	18.90B
Separate account assets	assets	7.45B
Reinsurance recoverables	assets	4.07B
Property and equipment	assets	3.70B
Other assets	assets	3.25B
Total assets	assets	153.27B
Total liabilities	liabilities	110.82B
Total equity	liabilities	42.44B
Total current liabilities	liabilities	52.61B
Long-term debt	liabilities	29.37B
Non-current insurance and contractholder liabilities	liabilities	9.78B
Separate account liabilities	liabilities	7.45B
Deferred tax liabilities, net	liabilities	6.85B
Other non-current liabilities	liabilities	4.77B
Noncontrolling interests	liabilities	232.00M
Total shareholders' equity	equity	42.21B
Treasury stock, value	equity	35.22B
Accumulated other comprehensive loss	equity	3.60B
Pharmacy and other service costs payable	liabilities	25.76B
Accounts payable	liabilities	9.88B
Accrued expenses and other liabilities	liabilities	8.98B
Current insurance and contractholder liabilities	liabilities	6.46B
Short-term debt	liabilities	1.53B
Aggregate	equity	81.02B
Retained earnings	equity	49.11B
Additional paid-in capital	equity	31.91B
Common stock, value, issued	equity	4.00M

Operating Activities – 3M 2026
Item	Value
Increase (decrease) in accounts and other receivables	2.15B
Net income	1.86B
Increase (decrease) in inventories	1.51B
Insurance liabilities	739.00M
Depreciation and amortization	650.00M
Increase (decrease) in reinsurance recoverable	104.00M
Increase (decrease) in other operating assets and liabilities, net	5.00M
Gain on sale of businesses	-11.00M
Increase (decrease) in deferred income taxes	-60.00M
Net investment gains (losses)	-258.00M
Accounts payable and accrued expenses and other liabilities	-988.00M
Pharmacy and other service costs payable	-4.57B

Investing Activities – 3M 2026
Item	Value
Proceeds from sale and maturity of other investments	426.00M
Debt securities and equity securities	185.00M
Debt securities and equity securities	54.00M
Divestitures, net of cash sold	20.00M
Commercial mortgage loans	2.00M
Payment for (proceeds from) other investing activity	-5.00M
Payments to acquire mortgage notes receivable	-39.00M
Payments to acquire equity method investments	-94.00M
Payments for (proceeds from) property, plant, and equipment	-267.00M
Payments to acquire debt and equity securities	-362.00M
Payments to acquire other investments	-557.00M

Financing Activities – 3M 2026
Item	Value
Issuance of common stock	57.00M
Deposits and interest credited to contractholder deposit funds	39.00M
Net change in short-term debt	-13.00M
Withdrawal from contract holders funds	-99.00M
Other, net	-158.00M
Total amount paid	-417.00M
Repayment of long-term debt	-550.00M

Cash Balance – 3M 2026
Item	Value
Cash and cash equivalents, beginning of period	7.74B
Cash and cash equivalents, end of period	7.08B